A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

被引：38
|
作者：
Chari, Ajai
Berdeja, Jesus G.
Oriol, Albert
van de Donk, Niels W. C. J.
Rodriguez, Paula
Askari, Elham
Mateos, Maria-Victoria
Minnema, Monique C.
Verona, Raluca
Girgis, Suzette
Prior, Thomas
Hilder, Brandi W.
Russell, Jeffery
Goldberg, Jenna D.
Krishnan, Amrita
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133873
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] GPRC5D CART cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial
    Zhang, Mingming
    Wei, Guoqing
    Zhou, Linghui
    Zhou, Jincai
    Chen, Siye
    Zhang, Wei
    Wang, Dongrui
    Luo, Xueping
    Cui, Jiazhen
    Huang, Simao
    Fu, Shan
    Zhou, Xinkai
    Tang, Yu
    Ding, Xiaomin
    Kuang, Jiao
    He, Xiaowen Peter
    Hu, Yongxian
    Huang, He
    LANCET HAEMATOLOGY, 2023, 10 (02): : E107 - E116
  • [42] Updated results of a phase 1, first-in-human study of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma
    Voorhees, Peter
    Shah, Nina
    D'Souza, Anita
    Rodriguez, Cesar
    Weisel, Katja
    Teipel, Raphael
    Hurd, David
    Bueno, Orlando
    Pumford, Neil
    Rosenberg, Tanya
    Pothacamury, Rajvineeth Kumar
    Ross, Jeremy
    Polepally, Akshanth
    Lee, Shane
    Jin, Ziyi
    Talati, Chetasi
    Kumar, Shaji
    Vij, Ravi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S34 - S34
  • [43] Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial
    Xia, Jieyun
    Li, Hujun
    Yan, Zhiling
    Zhou, Dian
    Wang, Ying
    Qi, Yuekun
    Cao, Jiang
    Li, Depeng
    Cheng, Hai
    Sang, Wei
    Zhu, Feng
    Sun, Haiying
    Chen, Wei
    Qi, Kunming
    Yan, Dongmei
    Qiu, Tingting
    Qiao, Jianlin
    Yao, Ruosi
    Liu, Yang
    Wang, Xue
    Zhang, Yanlei
    Peng, Shuixiu
    Huang, Chih-Hua
    Zheng, Junnian
    Li, Zhenyu
    Chang, Alex H. H.
    Xu, Kailin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2583 - +
  • [44] Talquetamab (Tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study
    Searle, Emma
    Quach, Hang
    Biran, Noa
    Perrot, Aurore
    Berdeja, Jesus G.
    Dorritie, Kathleen
    Van Elssen, Catharina
    Touzeau, Cyrille
    Anguille, Sebastien
    Vishwamitra, Deeksha
    Nguyen, Ashley
    Ghosh, Debopriya
    Shearin, Elizabeth
    Mason, Gary E.
    Renaud, Thomas
    Matous, Jeffrey
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S550
  • [45] Talquetamab, a GPRC5DXCD3 Bispecific Antibody, for Treatment of Relapsed/Refractory Multiple Myeloma in Patients With Prior Exposure to BCMA Targeted Therapies - a "Real World" Study
    Shkury, Eden
    Hellou, Tamer
    Nevo, Lee
    Avigdor, Abraham
    Magen, Hila
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S88 - S89
  • [46] A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
    Sun, Mingyuan
    Qi, Junyuan
    Qiu, Lugui
    Jin, Jie
    Li, Xin
    Wei, Yongqiang
    Zhang, Guimin
    Liu, Xue
    Yin, Shaohong
    BLOOD, 2023, 142
  • [47] Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
    Ye, Jing Christine
    Schinke, Carolina
    Touzeau, Cyrille
    Minnema, Monique
    van de Donk, Niels
    Rodriguez-Otero, Paula
    Mateos Manteca, Maria-Victoria
    Rasche, Leo
    Vishwamitra, Deeksha
    Singh, Indrajeet
    Qin, Xiang
    Campagna, Michela
    Hilder, Brandi
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S99 - S99
  • [48] Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Garfall, Alfred L.
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    Nahi, Hareth
    van de Donk, Niels W. C. J.
    San-Miguel, Jesus F.
    Rocafiguera, Albert Oriol
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Goldberg, Jenna D.
    Banerjee, Arnob
    Krishnan, Amrita
    BLOOD, 2020, 136
  • [49] Anti-BCMA/GPRC5D bispecific CART cells in patients with relapsed or refractory multiple myeloma: a single-arm single-centre, phase 1 trial
    Zhou, Dian
    Sun, Qian
    Xia, Jieyun
    Gu, Weiying
    Qian, Jun
    Zhuang, Wanchuan
    Yan, Zhiling
    Cheng, Hai
    Chen, Wei
    Zhu, Feng
    Qi, Kunming
    Li, Depeng
    Sang, Wei
    Zhu, Lili
    Ma, Sha
    Li, Hujun
    Zhang, Huanxin
    Qiu, Tingting
    Yan, Dongmei
    Zhang, Yanlei
    Peng, Shuixiu
    Chang, Alex H.
    Xu, Kailin
    Li, Zhenyu
    LANCET HAEMATOLOGY, 2024, 11 (10): : e751 - e760
  • [50] Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody
    Dekhtiarenko, Iryna
    Lelios, Iva
    Jacob, Wolfgang
    Schneider, Meike
    Weisser, Martin
    Carlo-Stella, Carmelo
    Manier, Salomon
    Harrison, Simon J.
    Popat, Rakesh
    Riley, Anna Caroline Hasselbalch
    Broeke, Ann-Marie E.
    BLOOD, 2023, 142
12345